Amplifon (AMFPF) Stock Price, News & Analysis

Company Overview

Amplifon is a global leader in hearing care, specializing in the retail and distribution of hearing aids, accessories and related services. The company offers a full suite of solutions including diagnostic hearing assessments, personalized hearing aid fittings, follow-up care, tinnitus management and hearing protection. Through its network of branded stores and partner outlets, Amplifon serves individuals across the full spectrum of hearing needs, from prevention and early detection to long-term aftercare.

Founded in Milan in 1950 by Algernon Charles Holland, Amplifon has grown from a single audiology centre into a multinational organization. The company was listed on the Borsa Italiana in 2001 and has since expanded its footprint through targeted acquisitions and organic growth. Over the decades, Amplifon has integrated complementary businesses and technologies, reinforcing its position in an increasingly competitive global hearing-care market.

Today, Amplifon operates thousands of points of sale across more than 20 countries spanning Europe, North America, Latin America and the Asia-Pacific region. Headquartered in Milan, the company combines local retail expertise with global best practices in audiology, consumer engagement and after-sales support. Its international platform enables consistent service delivery and innovation in hearing solutions tailored to diverse regulatory environments and patient needs.

Key Stats

• Today's Range: $12.01 to $12.01
• 50-Day Range: $10.09 to $12.61
• 52-Week Range: $9.46 to $23.85
• Volume: N/A
• Average Volume: 38 shs
• Market Capitalization: $2.64 billion
• P/E Ratio: 15.40
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Amplifon Stock Analysis - MarketRank™

Amplifon scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amplifon has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Amplifon has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 20.00%

Earnings Growth

Earnings for Amplifon are expected to grow by 20.00% in the coming year, from $3.80 to $4.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amplifon is 15.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amplifon is 15.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.29.

Price to Book Value per Share Ratio

Amplifon has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.99% of the float of Amplifon has been sold short.

Short Interest Ratio / Days to Cover

Amplifon has a short interest ratio ("days to cover") of 313.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Amplifon has recently decreased by 1.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amplifon does not currently pay a dividend.

Dividend Growth

Amplifon does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: N/A

News Sentiment

Amplifon has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Amplifon this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amplifon insiders have not sold or bought any company stock.

Percentage Held by Institutions

Amplifon has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 6/01/2026
• Today: 6/06/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:AMFPF
• CIK: N/A
• Web: corporate.amplifon.com
• Phone: (390) 257-4721
• Fax: N/A
• Employees: 15,070
• Year Founded: 1950

Profitability

• EPS (Trailing Twelve Months): $0.78
• Trailing P/E Ratio: 15.40
• Forward P/E Ratio: 3.16
• P/E Growth: N/A
• Net Income: $157.31 million
• Net Margins: 2.87%
• Pretax Margin: N/A
• Return on Equity: 16.04%
• Return on Assets: 4.20%

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 0.48
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $2.71 billion
• Price / Sales: 0.97
• Cash Flow: $2.44 per share
• Price / Cash Flow: 4.92
• Book Value: $5.52 per share
• Price / Book: 2.18

Miscellaneous

• Outstanding Shares: 219,940,000
• Free Float: N/A
• Market Cap: $2.64 billion
• Optionable: Not Optionable
• Beta: 0.68